Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 1
2013 2
2014 12
2015 9
2016 13
2017 15
2018 14
2019 7
2020 15
2021 15
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30386435

97 results

Results by year

Filters applied: . Clear all
Page 1
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B, Medin J, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Silva D, Zivadinov R; MS-MRIUS Study Group. Weinstock-Guttman B, et al. CNS Drugs. 2018 Jan;32(1):75-84. doi: 10.1007/s40263-017-0482-4. CNS Drugs. 2018. PMID: 29270772 Free PMC article.
Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients.
Jamroz-Wiśniewska A, Zajdel R, Słowik A, Marona M, Wnuk M, Adamczyk-Sowa M, Adamczyk B, Lasek-Bal A, Puz P, Stęposz A, Krzystanek E, Patalong-Ogiewa M, Pokryszko-Dragan A, Budrewicz S, Koziarska D, Karbicka A, Wawrzyniak S, Fryze W, Furtak-Niczyporuk M, Rejdak K. Jamroz-Wiśniewska A, et al. J Clin Med. 2021 Apr 22;10(9):1830. doi: 10.3390/jcm10091830. J Clin Med. 2021. PMID: 33922368 Free PMC article.
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Wiertlewski S, Brochet B, Ruet A, Defer G, Derache N, Vermersch P, Zephir H, Debouverie M, Mathey G, Berger E, Cappé C, Labauge P, Carra C, De Seze J, Bigaut K, Brassat D, Lebrun-Frenay C. Cohen M, et al. Mult Scler. 2021 Sep;27(10):1556-1563. doi: 10.1177/1352458520969145. Epub 2020 Oct 30. Mult Scler. 2021. PMID: 33124504
Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study.
Horakova D, Uher T, Krasensky J, Seidl Z, Ribbens A, Van Hecke W, Billiet T, Koendgen H, Freudensprung U, Hyde R, Vaneckova M. Horakova D, et al. Mult Scler Relat Disord. 2020 Nov;46:102543. doi: 10.1016/j.msard.2020.102543. Epub 2020 Sep 28. Mult Scler Relat Disord. 2020. PMID: 33296966 Free article.
97 results